Biological Drugs Market Report 2025 (Global Edition)

Global Biological Drugs Market Report 2024 Market Size Split by Therapeutic Protein Outlook: (Levemir, Neulasta, Eylea, Rebif, NovoLog, Enbrel, Avonex, Neupogen, Humalog, Victoza, Lantus, Epogen, Aran...

Biological Drugs Market Report Description

We have various report editions of Biological Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Biological Drugs Market Insights Video

Competitive Landscape of the Biological Drugs Market

In the Biological Drugs market's competitive landscape, numerous key competitors are driving innovation and growth. Constant investment in R&D is crucial to staying competitive in this market. Companies are increasingly focusing on precision medicine, targeted biologics, and therapies for rare and orphan diseases, where market demand remains high. As the market continues to grow, driven by increasing demand for advanced treatments for chronic and rare diseases, companies will need to focus on innovation, cost efficiency, and strategic collaborations to stay competitive.

In August 2021, Pfizer Inc. and BioNTech SE announced that they had initiated a supplemental Biologics License Application with the FDA for the approval of a booster dose of COMIRNATY to prevent COVID-19 in individuals aged 16 and older. (Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission )

Top Companies Market Share in Biological Drugs Industry: (In no particular order of Rank)

• Samsung Biologics
• Amgen Inc.
• Novo Nordisk A/S
• AbbVie Inc.
• Sanofi
• Johnson & Johnson Services
• Inc.
• Celltrion Healthcare Co.
• Ltd.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann La-Roche Ltd.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Biological Drugs Market

Which Region Dominates the Biological Drugs Market in 2024?

According to Cognitive Market Research, North America currently dominates the Biological Drugs market, and the region is expected to have significant growth during the projected period. North America, especially the United States, is home to one of the most advanced healthcare systems worldwide. The region features state-of-the-art healthcare facilities, prominent pharmaceutical companies, and leading research institutions that play a crucial role in the development and distribution of biological drugs. The substantial healthcare expenditure in North America—particularly in the U.S.—supports the growth of the market for innovative treatments, including biologics. In 2022, health spending in the U.S. rose by 4.1%, reaching $4.5 trillion, or $13,493 per capita. This growth rate aligns with pre-pandemic levels (4.1% in 2019). Overall, health spending accounted for 17.3% of GDP in 2022, which is close to pre-pandemic proportions (17.5% in 2019) after experiencing a spike in 2020 (19.5%) and 2021 (18.2%), thereby fostering a strong demand for effective biologic therapies.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). As the Asia Pacific region experiences an aging population and increasing urbanization, the prevalence of chronic diseases is rising. Conditions such as cancer, rheumatoid arthritis, diabetes, and cardiovascular diseases are becoming more common, which is driving the demand for advanced therapies like biologics. In 2022, India alone was projected to report 1,461,427 new cancer cases, with a crude incidence rate of 100.4 per 100,000 individuals. Approximately one in nine individuals in India is expected to be diagnosed with cancer in their lifetime. The cancer burden in India is anticipated to increase from 26.7 million DALYs (disability-adjusted life years) in 2021 to 29.8 million in 2025, with the greatest impact in the northern and northeastern regions. Among non-communicable diseases, cardiovascular diseases account for the highest death rate (63.3%), followed by cancer (18.1%). Biologic drugs are increasingly being utilized to treat these long-term conditions, providing effective alternatives to traditional therapies.

The current report Scope analyzes Biological Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Biological Drugs

According to Cognitive Market Research, the global Biological Drugs market size was estimated at USD 465142.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 186057.0 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Biological Drugs market with a market size of USD 146798.97 million in 2024 and is projected to grow at a CAGR of 6.8% during the forecast period. In the U.S., the demand for the Biological Drugs market is driven by the high prevalence of chronic diseases, advanced healthcare infrastructure, and significant investment in research and development by leading pharmaceutical companies.
• The Canada Biological Drugs market had a market share of USD 22326.8 million in 2024 and is projected to grow at a CAGR of 7.8% during the forecast period. In Canada, the demand for the Biological Drugs market is driven by the aging population, growing awareness of biologic therapies, and government support for innovative treatments through public healthcare funding.
• The Mexico Biological Drugs market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 16931.1 million in 2024.

Europe Biological Drugs

According to Cognitive Market Research, the global Biological Drugs market size was estimated at USD 465142.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 139542.7 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.

• The United Kingdom Biological Drugs market had a market share of USD 23443.1 million in 2024 and is projected to grow at a CAGR of 8.1% during the forecast period. In the UK, Biological Drugs sales witness an upswing due to the increasing prevalence of chronic diseases such as rheumatoid arthritis, diabetes, and cancer, coupled with strong government support for innovative therapies.
• The French Biological Drugs market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 12837.9 million in 2024.
• According to Cognitive Market Research, the German Biological Drugs market size was valued at USD 27629.4 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. In Germany, Biological Drugs surged due to the country's robust healthcare infrastructure, high healthcare expenditure, and strong focus on research and development.
• The Italy Biological Drugs market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 12000.6 million in 2024.
• The Russia Biological Drugs market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 21629.1 million in 2024.
• The Spain Biological Drugs market is projected to witness growth at a CAGR of 6.4% during the forecast period with a market size of USD 11442.5 million in 2024
• The Luxembourg Biological Drugs market is projected to witness growth at a CAGR of 7.4% during the forecast period, with a market size of USD 4325.8 million in 2024.
• The Portugal Biological Drugs market is projected to witness growth at a CAGR of 7.1% during the forecast period, with a market size of USD 2930.4 million in 2024.
• The Greece Biological Drugs market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 1674.5 million in 2024.
• The Rest of Europe's Biological Drugs market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 21629.1 million in 2024.

Asia Pacific Biological Drugs

According to Cognitive Market Research, the global Biological Drugs market size was estimated at USD 465142.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 106982.7 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.8% from 2024 to 2031.

• According to Cognitive Market Research, the China Biological Drugs market size was valued at USD 48142.2 million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. Biological Drugs surged in China due to the Strong government support for biotechnology through policies like the "Healthy China 2030" initiative promotes research and innovation in biologics.
• The Japan Biological Drugs market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 14763.6 million in 2024.
• The India Biological Drugs market had a market share of USD 12837.9 million in 2024 and is projected to grow at a CAGR of 12.6% during the forecast period. In India, the demand for the Biological Drugs Market is driven by the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders, along with increasing healthcare awareness.
• The South Korean Biological Drugs market is projected to witness growth at a CAGR of 9.9% during the forecast period, with a market size of USD 10698.2 million in 2024.
• The Australian Biological Drugs market is projected to witness growth at a CAGR of 10.5% during the forecast period, with a market size of USD 5563.1 million in 2024.
• The Southeast Asia Biological Drugs market is projected to witness growth at a CAGR of 11.8% during the forecast period, with a market size of USD 7381.8 million in 2024.
• The Rest of the Asia Pacific Biological Drugs market is projected to witness growth at a CAGR of 10.6% during the forecast period, with a market size of USD 7595.7 million in 2024.

South America Biological Drugs

According to Cognitive Market Research, the global Biological Drugs market size was estimated at USD 465142.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 23257.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Biological Drugs market size was valued at USD 9954.0 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. Biological Drugs flourished in Brazil due to the increasing healthcare infrastructure, and the adoption of biosimilars, which have made biologic treatments more affordable and accessible.
• Argentina's Biological Drugs market had a market share of USD 3907.2 million in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period. Argentina's rising healthcare needs, particularly for chronic and autoimmune diseases, along with government initiatives supporting the availability of biologics and biosimilars, drive the market.
• Colombia's Biological Drugs market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 2069.8 million in 2024.
• Peru's Biological Drugs market is projected to witness growth at a CAGR of 8.4% during the forecast period, with a market size of USD 1907.0 million in 2024.
• Chile's Biological Drugs market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 1674.5 million in 2024.
• The Rest of Latin America's Biological Drugs market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 3744.4 million in 2024.

Middle East and Africa Biological Drugs

According to Cognitive Market Research, the global Biological Drugs market size was estimated at USD 465142.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 9302.85 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

• The GCC Countries Biological Drugs market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 3981.6 million in 2024. Biological Drugs sales flourish due to government investments in healthcare infrastructure and biotechnology.
• The Egypt Biological Drugs market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 976.80 million in 2024.
• The South Africa Biological Drugs market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 1469.8 million in 2024. Biological Drugs sales flourished in South Africa due to the increasing prevalence of chronic conditions like HIV/AIDS, cancer, and cardiovascular diseases, along with improving healthcare access and government initiatives to promote biopharmaceutical innovation.
• The Turkey Biological Drugs market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 800.0 million in 2024.
• The Nigeria Biological Drugs market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 976.80 million in 2024.
• The Rest of the MEA Biological Drugs market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 1097.7 million in 2024.

Biological Drugs Market Analysis

How are Segments Performing in the Global Biological Drugs Market?

Biological Drugs Market Therapeutic Protein Segment Analysis

According to Cognitive Market Research, Levemir is likely to dominate the Biological Drugs Market over the forecast period. Levemir offers distinct benefits, including its ability to provide steady insulin levels throughout the day, which helps control blood sugar levels with fewer injections. It has a longer duration of action (up to 24 hours), which reduces the need for multiple daily injections compared to traditional insulins. Unlike human insulin, Levemir is a recombinant insulin analog that has been modified to provide a more consistent release and lower risk of hypoglycemia (low blood sugar), which improves its appeal to healthcare providers and patients.

Enbrel is the fastest-growing segment in the Biological Drugs Market. Autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis, and psoriatic arthritis, are becoming increasingly common worldwide. Enbrel, a tumor necrosis factor (TNF) inhibitor, is highly effective in managing the inflammatory processes associated with autoimmune diseases, making it a cornerstone therapy for conditions like rheumatoid arthritis and psoriasis. The growing number of patients diagnosed with these conditions is directly driving the demand for Enbrel, as it offers a highly effective solution for managing chronic inflammation and improving quality of life.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Biological Drugs Industry. Request a Free Sample PDF!

Biological Drugs Market Monoclonal Antibody Segment Analysis

According to Cognitive Market Research, the Avastin segment holds the largest share of the market. Avastin is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein that promotes the growth of blood vessels that tumors need to grow and spread. By inhibiting VEGF, Avastin helps to prevent the formation of new blood vessels (angiogenesis) that supply nutrients to tumors, effectively slowing their growth and metastasis. Avastin is highly effective in treating several types of cancer, including colon cancer, lung cancer, breast cancer, kidney cancer, glioblastoma, and cervical cancer. Its versatility in treating a wide range of cancer types makes it a cornerstone in cancer therapy, increasing its demand and adoption across the oncology market.

In the Biological Drugs Market, Rituxan has been expanding at a rapid pace. Rituxan is a monoclonal antibody that targets CD20, a protein found on the surface of B-cells, which are involved in the pathogenesis of several diseases. By binding to CD20, Rituxan destroys the B-cells, which play a crucial role in the progression of diseases like non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis, and microscopic polyangiitis. Rituxan’s ability to target and eliminate malignant or autoimmune-activated B-cells makes it highly effective in treating both cancerous conditions and autoimmune diseases, providing relief for patients suffering from these complex, chronic diseases.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Biological Drugs Vaccine Outlook: Segment Analysis

Biological Drugs Market Vaccine Segment Analysis

According to Cognitive Market Research, The Gardasil segment holds the largest market share. HPV is a leading cause of various cancers, including cervical cancer, anal cancer, oropharyngeal cancer, and penile cancer. The Gardasil vaccine, which protects against HPV types 6, 11, 16, and 18, has become a cornerstone in preventing HPV-related cancers. Types 16 and 18 are responsible for approximately 70% of cervical cancers, while types 6 and 11 cause about 90% of genital warts. As awareness increases about the link between HPV and these cancers, more people are opting for the Gardasil vaccine as a preventive measure, driving market growth.

In the Biological Drugs market, the rapidly growing sector is the Fluzone category. Seasonal influenza is a significant public health concern globally, causing millions of illnesses and thousands of deaths annually. The World Health Organization (WHO) estimates that influenza causes 3–5 million severe cases and 290,000–650,000 respiratory deaths worldwide each year. The Fluzone vaccine, developed by Sanofi Pasteur, is a key preventative measure against influenza, offering protection against multiple strains of the virus. As influenza continues to impact populations annually, demand for effective vaccines like Fluzone remains high.

• Gardasil
• Prenvar 13
• Fluzone
• Cervarix
• Varivax

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion